HIV
-
MedCity Pivot Podcast: A conversation with Gilead Sciences VP Anu Osinusi
Gilead Sciences is a leader in the field of virology treatments. As VP of clinical research for hepatitis, respiratory and emerging viruses at Gilead, Anu Osinusi talked about the pharma company’s work in HIV and hepatitis and how her personal background informed her team’s work in developing a Covid-19 treatment.
-
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
-
J&J HIV vaccine fails study in Africa, but a separate clinical trial continues in Europe, Americas
Johnson & Johnson reported results from a mid-stage study in southern Africa showing just 25% efficacy for its HIV vaccine. J&J developed the HIV vaccine with the same technology used in its successful Ebola and Covid-19 vaccines.
-
Gilead’s Gritstone vaccine deal adds yet another shot on goal for HIV cure
The therapeutic vaccine will be based on Gritstone Oncology’s technology and will use antigens from Gilead Sciences. It’s the latest in a string of partnerships Gilead has signed in its search for an HIV cure.
-
Gilead got a boost from a newly approved PrEP drug. Now, a major insurer is dropping coverage
UnitedHealthcare sent a notice to plan members stating that it would no longer cover Descovy to prevent HIV, while Truvada – after it goes generic next month – will be covered for free. Gilead reported that Descovy for PrEP had offset a second-quarter fall in product sales.
-
ViiV’s twice-monthly injected PrEP drug superior in HIV prevention to Gilead daily pill, analysis shows
The company said Tuesday that a final analysis of its Phase IIb/III study of cabotegravir showed greater efficacy in HIV prevention than Gilead’s Truvada. The study, among men and transgender women who have sex with men, was stopped in May following an interim analysis.
-
ViiV injected drug appears better than Gilead’s pill at preventing HIV
A Phase IIb/III study sponsored by NIAID is being stopped early after an interim analysis indicated that injected cabotegravir provided better protection than Gilead’s Truvada.
-
Researchers question cost-effectiveness of Gilead’s newly approved PrEP drug for preventing HIV
A study, published Monday, found that when generic versions of Gilead’s Truvada become available, payers should only be willing to pay a few hundred dollars more per year for Descovy, approved for PrEP in October, despite the latter’s better toxicity profile.
-
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
-
Facebook takes down misleading ads about HIV-prevention drug
News media reported that the social media company began taking down ads for lawsuits against Gilead Sciences regarding the drug Truvada following widespread outcry from LGBT and HIV groups and health experts.
-
FDA turns down ViiV Healthcare’s injectable HIV drug
In an announcement over the weekend, the British drugmaker said the FDA had cited manufacturing issues in its complete response letter for cabotegravir and rilpivirine.
-
HHS rolls out program to provide HIV-prevention drugs free of charge
The Ready, Set, PrEP program is designed to provide Gilead Sciences’ Truvada and Descovy to up to 200,000 people who do not have prescription drug insurance coverage. Gilead is donating supplies of both drugs.
-
NIH, Gates Foundation invest $200M to develop gene therapies for developing countries
The partnership will have a particular focus on therapies to treat sickle cell disease and HIV, with each party committing $100 million to the effort.
-
Administration stops NIH scientists from obtaining fetal tissue, possibly threatening HIV research
Science magazine reported that the move put the brakes on a preclinical HIV study and follows the cancellation of a contract between the FDA and a California-based company that supplies fetal tissue for medical research.